Interindividual variation in prostate cancer (PCa) susceptibility may be modulated in part through genetic polymorphisms in the DNA repair genes, especially the genes involved in the base excision repair and nucleotide excision repair pathway. Two of the common single-nucleotide polymorphisms X-ray repair crosscomplementing group 1 (XRCC1) and Xeroderma pigmentosum group D (XPD) genes in PCa, which is one of the most common neoplasias in men all over the world, have been studied. In a case-control study of 171 PCa patients and 200 age-matched healthy controls, of similar ethnicity, genotyping was done to determine XPD exon 10 (G23592A), exon 23 (A35931C), and XRCC1 exon 6 (C26304T), exon 9 (G27466A), exon 10 (G23591A) gene polymorphisms by amplification refractory mutation-specific and polymerase chain reaction-restriction fragment length polymorphism methods, respectively. We observed that XPD exon 10 variant AA genotype was associated with increased risk for PCa (adjusted odds ratio [OR] 2.63, 95% confidence interval [95% CI] 1.40-4.92, p ¼ 0.003), and XRCC1 exon 9 GA genotype was also statistically associated with PCa (adjusted OR 2.61, 95% CI 1.53-4.43, p < 0.001). However, XPD exon 23 (A>C) and XRCC1 exon 6 (C>T) and exon 10 (G>A) did not have significantly increased risk for PCa. The haplotype analysis of XPD exon 10 and exon 23 G-C (OR 3.44, 95% CI 2.15-5.51, p < 0.0001) and A-A (OR 4.96, 95% CI 3.08-7.98, p < 0.0001) was associated with a significant increase in PCa risk. Similarly, the combined analysis of XRCC1 exon 6, exon 9, and exon 10 C-G-A (OR 2.93, 95% CI 1.91-4.50, p < 0.001) and C-A-G (OR 2.48, 95% CI 1.62-3.80, p < 0.001) demonstrated statistically significant risk in PCa. XRCC1 exon 9 GA genotype showed protective association with high grade of PCa. Our results suggest a positive association of XRCC1 exon 9 and XPD exon 10 genotypes that may play an important role in the pathophysiology and may modulate the risk of PCa.
Introduction
P rostate cancer (PCa) is the most common noncutaneous malignancy and the second leading cause of cancer mortality in Western men ( Jemal et al., 2005) . However, in India, its incidence is low, and it is ranked as the sixth most commonly diagnosed cancer in men . Despite its high morbidity, the etiology of PCa remains largely unknown. Risk of PCa varies with age, ethnicity, family history, and diet (Shields and Harris, 1991) . It is well established that genetic factors also play an important role in pathogenesis of PCa. A high proportion of cancer burden may be attributed to low penetrance genes .
Various DNA alterations can be caused by exposure to environmental and endogenous carcinogens. Most of these alterations, if not repaired, can result in genetic instability, mutagenesis, and cell death. DNA repair pathways play a critical role in maintaining the genomic integrity in general and specialized functions of cells as well as in the prevention of carcinogenesis, and therefore defect in these genes can lead to higher susceptibility to multiple cancers (Shields and Harris, 1991) .
Bulky adduct lesions induced by chemical carcinogens are repaired through the nucleotide excision repair pathway (Sancar and Tang, 1993) . Base damage and DNA singlestrand breaks are repaired through the base excision repair (BER) pathway (Evans et al., 1997) . These pathways are a multistep process that requires the activity of several proteins. The DNA repair function of xeroderma pigmentosum group D (XPD) is critical for repairing genetic damage from tobacco and other carcinogens. The XPD protein is a component of cotranscription factor IIH and has a DNAdependent helicase activity (Benhamou and Sarasin, 2005) . The two XPD polymorphic loci that have been of particular interest in molecular epidemiological studies are Asp312Asn and Lys751Gln polymorphisms (Wang et al., 2009a) . X-ray repair cross-complementing group 1 (XRCC1) protein has no known catalytic activity but serves to orchestrate BER via its role as a central scaffolding protein for DNA ligaseIII (Masson et al., 1998) Located at chromosome 19q13.2, XRCC1 has numerous single-nucleotide polymorphisms (SNPs), having three common SNPs influencing amino acid substitutions in exon 6 (Arg194Trp), exon 9 (Arg280His), and exon 10 (Arg399Gln), respectively (Wang et al., 2009b) . These nonconservative amino acid alterations may influence DNA repair capacity (DRC) by altering the protein-protein interactions between XRCC1 and other BER proteins. The 19q13 region has been found to be related in PCa susceptibility by genome-wide association study .
On the basis of the key role the XRCC1 and XPD genes play in DNA repair mechanisms, we propose that variation in these genes may be associated with PCa susceptibility. The frequency of different polymorphic variants varies with the ethnicity of a population, so results may vary in different parts of the world. Acquaintance of frequency of polymorphisms in a population is thus of prime importance. Therefore, we evaluated the associations between the polymorphisms and their haplotypes with PCa risk in north Indian population.
Materials and Methods

Study subjects
Patients were enrolled in the Department of Urology (Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India) between January 2006 and December 2008. The participants in this study were unrelated individuals of similar ethnicity from Lucknow and other adjoining cities of north India. All men symptomatic for lower urinary tract infection and suspected to have PCa based on serum prostatespecific antigen (PSA >4 ng=mL) and=or abnormal digital rectal examination underwent transrectal systematic ultrasound-guided needle biopsies. The primary end point was the histologic presence of adenocarcinoma of the prostate in the biopsy specimen. Tumor grade was evaluated in PCa samples by the Gleason scoring system . The two most common pattern of growth (well differentiated and poorly differentiated) were combined to get a score. A total of 171 histologically confirmed PCa patients were enrolled for the study. Bone scan was conducted in patients suspected with bone metastasis. The study was approved by the Ethical Committee Review Board of our institute, and informed consent was obtained from each participant. The study also enrolled 200 unrelated, agematched healthy control individuals of similar ethnicity. Serum PSA was done in all the control individuals, and those with total PSA !4 ng=mL, or with history of cancer, were excluded from the study. Serum PSA was done using CanAg PSA EIA Kit (Fujirebio Diagnostics AB, Goteborg, Sweden).
DNA extraction and genotyping
Five milliliters of peripheral blood samples was collected in ethylenediaminetetraacetic acid vials from patients as well as controls and was stored at À708C. The genomic DNA was extracted from the stored peripheral blood samples using salting out method . Genotyping was performed using amplification refractory mutation-specific polymerase chain reaction (PCR) methodology for XPD exon 10 (G>A) (Rybicki et al., 2004) . Each PCR was carried out in a total volume of 12 mL. XPD exon 23 (A>C) was genotyped by PCR-restriction fragment length polymorphism methods using PstI (New England Biolabs, Beverly, MA) restriction enzyme . XRCC1 exon 6 (C>T), exon 9 (G>A), and exon 10 (G>A) (Chacko et al., 2005) were also genotyped by PCR-restriction fragment length polymorphism methodology using PvuII, RsaI, and MspI restriction enzymes, respectively (New England Biolabs). The PCR products were checked on 2.0% agarose gels stained with ethidium bromide.
Quality control
To validate the genotype, 10% of randomly selected samples were replicated by other lab personnel. The results were reproducible with >99% concordance of results.
Statistical analyses
The sample size was calculated and was found to be adequate using QUANTO software, version 1.0 (http:== hydra.usc.edu=gxe) for the genetic marker. Sample size achieved 80% of the statistical power. A two-tailed p-value <0.05 was considered statistically significant. Chi-square (w 2 ) analysis was used to assess deviation from Hardy- 
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Weinberg's equilibrium and to compare the genotype=allele= haplotype frequency between patients and controls. Odds ratios (ORs) were obtained by unconditional logistic regression analysis and adjusted for age and smoking as a continuous variable. PCa patients with different Gleason grades= bone metastasis were identified using the same statistics as mentioned. All the statistical analyses were conducted using the SPSS software, version 11.5 (SPSS, Chicago, IL) . A p-value <0.05 was regarded statistically significant.
Haplotype analysis
Haplotypes were constructed and their frequencies assessed using the maximum-likelihood method, using an expectation-maximization algorithm by performing 100,000 permutations through software Arlequin (Version 2.0). OR was calculated using unconditional logistic regression for risk haplotypes taking the wild-type haplotype as reference.
Results
Demographic and clinical details of study subjects
There was no statistical difference between age of the patients (59.1 AE 10.4 years) and healthy controls (62.6 AE 8.9 years) and smoking habits. As expected, there was a high degree of statistical difference between serum PSA of PCa patients (221 AE 57.4 ng=mL) and controls (2.3 AE 0.8 ng=mL) . The majority of patients had a high Gleason grade at the time of diagnosis (Gleason score 7 in 30.8% of PCa and Gleason score >7 in 39.6% PCa); 42.1% of the patients were diagnosed to have bone metastasis (Table 1) . XPD, xeroderma pigmentosum group D; XRCC1, X-ray repair cross-complementing group 1. 
Association of XPD and XRCC1 genotype variants with PCa risk
The genotypic distributions of XPD and XRCC1 gene polymorphisms in the controls were in Hardy-Weinberg equilibrium except for XRCC1 exon 9 ( Table 2 ). This is in accordance with an earlier study . The genotypic frequency distribution between cases and controls for XPD and XRCC1 is given in Tables 3 and 4, We also observed significant difference in XRCC1 exon 9 and exon 10 gene variants ( p < 0.01, p ¼ 0.041, respectively) between cases and controls. GA genotype of XRCC1 exon 9 showed 2.6-fold (95% CI 1.53-4.43, p < 0.001) increased risk for PCa. XRCC1 exon 10 and XRCC1 exon 6 genotype variants did not demonstrate any significant risk associated with PCa.
Association of XPD and XRCC1 haplotypes with PCa risk
Haplotype results demonstrated that XPD exon 10 G-exon 23 C (G-C) haplotype was associated with 3.44-folds (OR 3.44, 95% CI 2.15-5.51, p < 0.0001) and XPD haplotype A-A was associated with 4.96-folds (OR 4.96, , p < 0.0001) risk for PCa (Table 3) . Our results also established 2.93-fold (OR 2.93, 95% CI 1.91-4.50, p < 0.001) and 2.48-fold (OR 2.48, 95% CI 1.62-3.80, p < 0.001) increased risk for PCa for XRCC1 haplotypes C-G-A (XRCC1 exon 6 C-exon 9 Gexon 10 A) and haplotype C-A-G, respectively (Table 4) .
Analysis of XPD and XRCC1 polymorphism with risk for higher grades For genotypic comparison, the patients with different Gleason grades were subcategorized into three groups (low grade <7, intermediate grade 7, and high grade >7) based on the degree of differentiation between cells. When the genotype frequencies of XPD and XRCC1 variants were compared between these three Gleason groups, we did not find any significant risk associated with higher grades of disease XRCC1 AND XPD GENE POLYMORPHISM IN PROSTATE CANCER (Tables 5 and 6 ). However, XRCC1 exon 9 showed significant protective association with high grade of PCa (OR 0.41, 95% CI 0.17-0.99, p ¼ 0.047).
Analysis of XPD and XRCC1 polymorphism with risk for bone metastasis
We also studied XPD and XRCC1 gene variants and their risk associated with bone metastasis. The PCa patients were divided into two groups, one with bone metastasis and the other with nonmetastasis. When these two groups were analyzed for risk of susceptibility for bone metastasis with XPD exon 10, 23, and for XRCC1 in exon 6, 9, and 10, our study did not confirm any significant association for PCa metastasis risk (Tables 7 and 8 ).
Interaction of XPD and XRCC1 polymorphism with smoking
We evaluated the gene-smoking interaction to study the modulation of PCa risk with respect to XPD and XRCC1 polymorphisms. We divided the PCa patients into two groups, one nonsmokers (never smoked) and the other smokers (smoking more than 5 years). On analyzing the two groups for susceptibility to PCa, no significant association was observed (Table 9 ). 188 MANDAL ET AL.
Discussion
Common genetic SNPs or mutations in the DNA repair system play a major role in tumorigenesis. Polymorphisms in XRCC1 and XPD genes have been studied in relation to the risk for cancers of the head and neck, breast, and skin (Sturgis et al., 1999; Winsey et al., 2000; Tang et al., 2002) . It is therefore suspected that some genetic variants of DNA repair genes might contribute to PCa pathogenesis.
The genotype frequency in healthy controls in our study was consistent with the other reported Indian studies on XPD and XRCC1 . Further, our results demonstrated that XPD exon 10 AA was significantly associated with increased risk of PCa (OR 2.61, p ¼ 0.003). Bau et al. (2007) also observed AA of XPD exon 10 to be associated with the development of PCa. Similarly, XPD exon 10 A allele has been reported to be associated with increased risk of oral leucoplakia and bladder cancer in India (Majumder et al., 2007) . The other polymorphic site of XPD, exon 23, did not show any association with PCa. Ritchey et al. (2005) also reported no significant association of XPD exon 23 with risk of PCa. We did not observe XPD exon 10 and exon 23 gene polymorphisms to be associated with susceptibility to higher grade or bone metastasis. This suggested that XPD exon 10 gene variants may be associated with initiation of PCa, but not with progression.
A meta-analysis of 38 case-control studies by Hu et al. (2005) concluded that the XRCC1 exon 6 variant had a protective effect on cancer risk, whereas individuals carrying the exon 9 variant allele had increased cancer risk compared to those with the wild-type genotypes. Another meta-analysis indicated that the XRCC1 exon 10 A allele might act as a recessive allele in its association with PCa risk (Geng et al., 2009) . However, in our study, we found that XRCC1 exon 9 heterozygous GA genotype was associated with increased risk of PCa. No risk was observed when homozygous variant allele was present. This clearly indicated that the risk observed in heterozygous genotype may be by chance. We did not observe any significant independent associations with PCa for XRCC1 exon 6 and XRCC1 exon 10 gene polymorphisms. XRCC1 exon 9 heterozygous GA genotype showed protective association with high grade PCa. No association for the rest of XRCC1 gene variants was observed with higher grade or bone metastasis. This is in accord with a recent study by Kowalski et al. (2009) where no altered risk was observed with the XRCC1 codon 194 and 399 genotypes individually with head and neck cancer. XRCC1 exon 10 has been shown to be associated with risk of PCa in many studies. Conflicting results obtained in our study may be due to ethnicity difference or the sample size. Though our study achieved sufficient (>80%) power due to the low incidence rate of PCa in India, a higher sample size may detect more modest differences.
Lifestyle-related habits like cigarette smoking, tobacco chewing, and alcohol consumption have been associated with PCa in various epidemiological reports (Andersson et al., 1996; Hickey et al., 2001) . However, in our study we did not observe any association of smoking with XRCC1 and XPD.
The haplotype analysis of XPD exons 10 and 23, two of the haplotypes (G-C and A-A), demonstrated higher risk with PCa. Similarly, haplotype analysis of XRCC1 exons 6, 9, and 10 haplotypes (C-G-A and C-A-G) showed statistically increased risk with PCa, but no altered risk was associated with other haplotypes. The combined genotype was associated with PCa.
In summary, we found increased risk of PCa in individuals with two copies of the XPD exon 10 A allele. We also observed that G>A genotype of the XRCC1 exon 9 gene variant was associated with PCa risk. The combined genotype of XPD exons 10 and 23 and XRCC1 exons 6, 9, and 10 was found to be associated with PCa risk. Although the sample size of our study may comparatively be small, modest effects cannot be ruled out. These results suggest that genetic variants involved in DNA repair pathways may also be involved in PCa etiology, particularly when the functions of two genes involved in different DNA repair pathways are both compromised. Additional studies of functional DNA repair gene polymorphisms are required to augment the etiology in the pathogenesis of PCa. Introduction P rostate cancer (PCa) is the most common non-skin cancer among men, with its incidence being variable in most countries (Hsing et al., 2000) . However, in India its incidence is low, and it ranks as the sixth most commonly diagnosed cancer in men . Despite its high incidence and morbidity, the etiology of PCa is still unknown. There is still limited data published on the mechanisms of carcinogenesis of PCa (Ribeiro et al., 2004; Bott et al., 2005) . However, it has been suggested that genetic polymorphisms may influence an individual's susceptibility to PCa.
DNA repair is an important mechanism for maintaining the integrity of DNA. The key DNA repair pathways that are often associated with cancer risk include base excision repair, nucleotide excision repair, and homologous recombination repair. Single nucleotide polymorphisms located in DNArepair genes could be responsible for serious alterations in DNA repair capacity (DRC) (Andreassen et al., 2002) . Several studies have demonstrated that polymorphisms in DNA repair genes that are responsible for maintaining genomic integrity are modifiers of disease risk Vodicka et al., 2004) .
The XRCC3 (located in the 14q32.3 region) gene product is involved in the homologous recombination and repair pathway. XRCC3 participates in DNA double-strand break (DSB)/recombination repair and is a member of the Rad-51-related protein family. Rad-51-like proteins are known to participate in homologous recombination to maintain chromosome stability and repair DNA damage (Manuguerra et al., 2006) . Carriers of the XRCC3 variant allele (exon7, C18067T) exhibit relatively high DNA adduct (covalent adducts between cancer causing chemicals and DNA) levels in lymphocyte DNA, indicating that this polymorphism may be associated with a relatively low DRC (Synowiec et al., 2008) . Molecular epidemiological studies have shown that this XRCC3 polymorphism is associated with increased risk of breast, gastric carcinoma (Kuschel et al., 2002; Shen et al., 2004) . Therefore, XRCC3 has been of considerable interest as a candidate susceptibility gene for cancer. Similarly, the XRCC7 gene product primarily participates in the repair of DSBs via the nonhomologous end-joining (NHEJ) mechanism (Khanna and Jackson, 2001) .
The XRCC7 gene (located on chromosome 8q12), also known as PRKDC (protein kinase, DNA-activated, catalytic polypeptide), encodes DNA-PKcs (protein kinases). As the catalytic subunit of the DNAPK complex, XRCC7 aids in the recognition and repair of DSBs. The variant allele G6721T in XRCC7 intron 8 may also represent an increased risk of cancer (Wang et al., 2004) .
In the present study, we investigated functional variants of XRCC3 and XRCC7 and their implication in the pathogenesis of PCa to augment the effects of individual polymorphisms and enhance cancer risk assessment in North Indian cohort.
Materials and Methods
Study subjects
The present study was hospital-based and both cases and controls were enrolled in the Department of Urology (Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow) between January 2007 and December 2009. The participants in this study were unrelated individuals of similar ethnicity from Lucknow and other adjoining cities of North India. All symptomatic men for lower urinary tract infection (LUTS) suspected to have PCa based on serum prostatespecific antigen (PSA) >4 ng/mL and/or abnormal digital rectal examination had transrectal systematic ultrasoundguided needle biopsies. The primary end point was the histologic presence of adenocarcinoma of the prostate in the biopsy specimen. Tumor grade was evaluated in PCa samples by the Gleason scoring system . The two most common patterns of growth (well differentiated and poorly differentiated) were combined to a score. A total of 192 histologically confirmed patients with PCa were enrolled for the study. Bone scan was conducted in patients suspected with bone metastasis.
We randomly selected 224 cancer free, unrelated, age matched healthy control individuals from similar ethnicity. PSA assay was done in all the control individuals, and those with total PSA !4 ng/mL or with a history of cancer were excluded from the study. Serum PSA was assayed by sandwich ELISA using Can gen PSA kit. Informed consent was obtained from each subject while interviewing for demographic details and blood sample collection. The institutional ethical committee approved this study.
DNA extraction and genotype analysis
Standard venipuncture was used to collect 5 mL of peripheral blood samples from all study participants in tubes containing ethylenediaminetetraacetic acid as an anticoagulant and stored at À708C. The genomic DNA was extracted from the stored peripheral blood samples using salting out method .
The polymorphic sites in XRCC3 (Exon 7 C18067T, rs861539 and IVS5-14 A17893G, rs1799796) and XRCC7 (Intron 8 G6721T, rs7003908) genes were amplified by polymerase chain reaction (PCR) combined with restriction fragment-length polymorphism using primers implying conditions, as previously described (Ló pez-Cima et al., 2007; Werbrouck et al., 2008) . PCR cocktail comprised of 10 pmol of each primer; 100 ng genomic DNA; 0.25 mM each of deoxyribonucleotide triphosphate; and 1Â PCR buffer containing 10 mM Tris-HCl, pH 8.6, 50 mM KCl, 1.5 mM MgCl 2 , and 0.5 units of Taq polymerase (Bangalore Genei). Amplified products were digested using restriction enzyme NcoI for XRCC3 Exon 7 (C > T) and PvuII (MBI Fermentas Inc.) for XRCC3 IVS5-14 (A > G) and XRCC7 Intron 8 (G > T), respectively. Subsequently, fragments of XRCC3 and XRCC7 were resolved on 10% PAGE and 2% agarose gels, to identify wild type and polymorphic variant.
Quality control procedures
Precise quality control procedures were applied during the genotyping process. As a negative control, a PCR mix without a DNA sample was used to ensure the accuracy of the method used. Samples that failed to genotype were scored as missing and subjected to repetition. Five percent of samples from patients and controls, including samples of each genotype, were sequenced to evaluate the quality of genotyping, which showed 100% concordance. Genotyping was performed without knowledge of the case or control status.
Statistical analyses
Power of the study was calculated using Quanto software version 1.0 (http://hydra.usc.edu/gxe) with input of the following variables; Case-Control Study Design, Significance Level (a) <0.05 (two-sided), Model of inheritance ¼ log additive, allele freq, and genetic effect for odds ratio (OR) (!1.6 or 0.6). The present study achieved 80% of the statistical power. A two-tailed p-value of <0.05 was considered statistically significant. Chi-square (w 2 ) analysis was used to assess deviation from Hardy-Weinberg's equilibrium and to compare the genotype/allele/diplotype frequency between patients and controls. ORs was obtained by unconditional logistic regression analysis and adjusted for age as a continuous variable. Patients with PCa and different Gleason grades or bone metastasis were identified using the same statistics as mentioned. Statistical significance was set at p < 0.05. All the statistical analysis was conducted using the SPSS software, version 11.5 (SPSS, Inc.).
Results
Demographical and clinical details of study subjects
A total of 416 individuals (192 PCa and 224 controls) were analyzed in the study. There was no statistical difference between age of the patients (59.1 AE 10.4 years) and healthy controls (62.6 AE 8.9 years) or their smoking habits ( p ¼ 0.327). As expected, there was high degree of statistical difference between serum PSA of patients with PCa (221 AE 57.4 ng/mL) and controls with PCa (2.3 AE 0.8 ng/mL). The majority of the patients had high Gleason grades at the time of diagnosis (Gleason score 7 in 29.7% of PCa, and Gleason score >7 in 44.8% of PCa), and 41.8% of patients were diagnosed to have bone metastasis (Table 1) .
Association of XRCC3 and XRCC7 genotype variants with PCa risk
The genotypic distributions of all three gene polymorphism in the controls were in Hardy-Weinberg's equilibrium. To evaluate the association between genetic variant with risk of PCa, we compared XRCC3 Exon 7, XRCC3 IVS5-14, and XRCC7 Intron 8 genotype frequency distribution in the PCa and control group is shown in 
Analysis of XRCC3 and XRCC7 gene polymorphism with risk for bone metastasis
Association between the XRCC3 Exon 7, IVS5-14, and XRCC7 Intron 8 gene variants and their risks associated with bone metastasis were also investigated. The patients with PCa were stratified into two groups, one with positive and the other with negative bone metastasis. These two groups, 
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however, demonstrated no association with any of these three gene polymorphisms with the risk of PCa ( Table 5 ).
Interaction of XRCC3 and XRCC7 polymorphism with smoking habit in PCa patients
We evaluated the gene-smoking interaction to study the modulation of PCa risk with regard to XRCC3 Exon 7, IVS5-14, and XRCC7 Intron 8 gene polymorphisms. We grouped the patients with PCa into two groups: nonsmokers (never smoked) and smokers (smoking for >5 years). On analyzing the genotype frequency between these two groups for susceptibility to PCa, none of these polymorphisms demonstrated association (data not shown).
Discussion
Cancer is a complex disease that is influenced by the interplay between multiple genetic and environmental factors, and, thus, it is unlikely that individual genes and/or single nucleotide polymorphisms would have substantial effects on the overall risk. Interest in recent years has focused on the population-wide variability in repair capacity phenotypes, which appears to account for a several-fold variation in cancer risk.
In this hospital-based case-control study, we examined the influence of DRC of homologous recombination (XRCC3-Exon7, XRCC3 IVS5-14) and NHEJ (XRCC7 Intron8) genes for PCa susceptibility. Our data revealed increased risk of PCa in individuals with GG genotype of the XRCC7 Intron 8. The combined genotype of XRCC3 Exon 7 and IVS5-14 was found to be associated with PCa risk.
Disruption of genomic integrity contributes to malignant transformation and subsequent cancer development. The repair of DNA damage plays a key role in maintaining genomic integrity. The role of the major DNA repair pathways is mainly responsible for the removal of bulky DNA adducts induced by chemical carcinogens (Aboussekhra et al., 1995; Wood, 1999) . These pathways thus involve sequential reaction steps, including DNA damage recognition, incision of damaged DNA, repair of the gapped DNA, and DNA ligation (Sancar et al., 2004) . The XRCC3 variant, T241M, has been reported to be associated with an increased risk of some cancers (Lindh et al., 2006) . However, a recent experimental study did not show a functional difference between the 241 variant and the common genotype of XRCC3 in homologous recombination repair of DNA in XRCC3-deficient irs1SF cells (or in sensitivity to the inter-strand cross-linking agent mitomycin C) (Shen et al., 2003) .
In our study, no significant association was observed with the susceptibility to PCa in XRCC3. Smoking too had no influence (data not shown). The genotype frequency in healthy controls in our study was consistent with the other reported Indian studies on XRCC3 and XRCC7 . However, the present study did not illustrate any significant risk between XRCC3 Exon 7 (C > T) and IVS5-14 (A > G) and PCa risk. Previous reports have suggested XRCC3 Exon 7 (C > T) polymorphism to be associated with melanoma development in Caucasians and with breast cancer in white Anglo-Saxons (Winsey et al., 2000; Kuschel et al., 2002) but not among South Australians and Japanese men with PCa (Tatsuya et al., 2008; Dhillon et al., 2009) .
To the best of our knowledge, there has been no report on association with the risk of PCa with XRCC3, IVS5-14 (A > G) gene polymorphism, which is found in noncoding regions. No significant association with XRCC3 IVS5-14 gene The XRCC7 gene is involved in the NHEJ pathway, which is responsible for repairing most DSBs (Hopfner et al., 2002) . The expression of XRCC7 is elevated in bladder tumor tissue and head and neck cancer cell lines (Sturgis et al., 1999; Stronati et al., 2001) . Therefore, the variants of the XRCC7 gene product, if functional, could be expected to have an effect on DSB repair and, thus, on carcinogenesis. Interestingly, we found that the variant genotype GG of XRCC7 Intron 8 had a strong significant association with PCa risk. This is in accordance with a recent study by and Wang et al. (2004) , who also reported significant risk with bladder cancer and glioma, respectively. Conversely, Hirata et al. (2007) did not observe altered risk with PCa. It is well known that frequency of gene polymorphism may vary among ethnic groups. Therefore, the difference in results between these studies may be due to ethnicity differences of the studied populations.
A significant increased risk was observed in G allele carriers with high Gleason grades. To the best of our knowledge, this is the first report demonstrating the risk of the XRCC7 Intron 8 gene polymorphism with PCa. Together, all of these observations suggest that the G allele is a significant risk factor. In support of the functional significance of the XRCC7 Intron 8 polymorphism, XRCC7 is thought to regulate splicing and may cause mRNA instability (Hopfner et al., 2002) . Another possibility is its linkage association with another functional genetic polymorphism. However, these hypotheses are yet to be investigated. Though our study achieved sufficient (>80%) power, as higher sample size might produce different results.
These results suggested that genetic variants involved in DNA repair pathways may also be involved in PCa etiology, particularly when the function of the two genes involved in different DNA repair pathways are both compromised. Additional studies of functional DNA repair gene polymorphisms are required to augment the etiology in the pathogenesis of PCa. 
RESULTS
• Our results demonstrated that presence of CASP9 − 1263 G allele was associated with reduced risk for prostate cancer (odds ratio 0.6, 95%CI 0.39-0.92, P = 0.02). Other variant CASP9 was not associated with prostate cancer risk.
• Coincidentally, the presence of CASP9 − 1263 G allele was associated with increased risk for progression of prostate cancer to bone metastasis (odds ratio − 2.28, 95%CI 1.14-4.53, P = 0.02).
• CASP8 -652 ( + / − ) genotype was associated with increased hazard for early development of hormone refractory prostate cancer (hazard ratio 2.44, 95%CI 1.2-5.85, P = 0.045).
CONCLUSION
• Our results support the hypothesis that variants of CASP9 may influence the susceptibility to prostate cancer and its progression to bone metastasis.
• CASP8 polymorphism may influence the progression of prostate cancer disease to a hormone refractory state.
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What's known on the subject? and What does the study add? Earlier, role of caspases in cancer initiation and progression was documented. However, our paper is the first to find association of caspase gene polymorphism in PCa progression and metastasis ( CASP 9-1263 G) . Moreover, our paper shows that the gene polymorphisms in the promoter region of the gene can play a major role in development of hormone refectory prostate cancer . Results from this pilot study may be revaluated, and may be applicable in clinical practice. The PCa subjects with presence of CASP 8 -652 (-/-) allele may not be good subjects for hormone therapy, therefore these patients can be given any other alternative therapy.
OBJECTIVE
• To investigate, by genotyping CASP8 ( − 652 6N del/ins) and CASP9 ( − 1263 A > G; − 293 19N del/ins), whether inactivation of apoptosis by genetic polymorphism of caspases 8 and 9 play an integral role in the mechanism of cancer development.
• To investigate the role of these polymorphisms in susceptibility to early development of hormone refractory prostate cancer.
PATIENTS AND METHODS
• The study included 175 histologically confirmed cases of prostate cancer and 198 age and ethnicity matched healthy controls.
• CASP9 − 1263 A > G polymorphism was genotyped using the polymerase chain reaction-restriction fragment length polymorphism method.
• CASP9 − 293 del/ins and CASP8 − 652 del/ ins polymorphisms were genotyped and the deletion pattern analysed by polyacrylamide gel electrophoresis.
INTRODUCTION
Prostate cancer (PCa) is one of the most common diseases of men. In India it is the sixth most commonly diagnosed cancer in men [1] . Variation in incidence and mortality rate from prostate cancer around the world suggests that it is multifactorial and polygenic in origin. The molecular events involved in neoplastic initiation and progression of PCa is poorly understood. Polymorphic variations in humans may be responsible for inter-individual differences in susceptibility to multifactorial diseases.
Apoptosis or programmed cell death is a crucial mechanism against hyperproliferation and malignancy [2] . Caspases are a family of highly conserved intracellular aspartate-specific cysteine proteases that are key intermediaries of the apoptotic process [3] . Various molecular epidemiological studies suggest that single-nucleotide polymorphisms (SNPs) may contribute to individual susceptibility to PCa by affecting either the expression or the activities of various enzymes [4] [5] [6] . However, the role of SNPs in major apoptosis-regulatory caspase genes in PCa remains unexplored.
Apoptosis has a central role in development of prostate, in the normal process of prostatic glandular self renewal and in the neoplastic process that occurs after androgen ablation [7] . Inappropriate or disordered apoptosis contributes to prostate carcinogenesis and progression to androgen-insensitive state of growth [3] .
Polymorphism in caspase 9 gene, variants in promoter region − 1263A > G (rs4645978) and − 293_-275del CGTGA GGTCAGTGCGGGGA (rs4645982) have been shown to be associated with susceptibility to lung cancer [8] . Whereas caspase 8 (CASP8; MIM 601763) is a key regulator of apoptosis or programmed cell death, an essential defence mechanism against hyper-proliferation and malignancy. Polymorphic variation in CASP8 has been reported to influence cancer risk. The − 652 6N AGTAAG ins-del promoter variant (rs3834129) has been associated with the risk of developing multiple tumour types in a Chinese population [9] .
We hypothesized that these genes and their haplotypes are involved in the initiation of apoptosis and therefore may be risk for PCa. Moreover, they may be involved in early advancement of PCa reaching hormone refractory state. In this study, the association of the two sites in caspase 9 -1263 A > G, − 293_-275delCGTGAGGTCAGTGCGGGGA ( − 293del) (rs4645978 and rs4645982) and caspase 8 − 652 6N ins/del polymorphisms (rs3834129)with the risk of PCa and its progression was evaluated in a hospital-based case control study of Northern India.
PATIENTS AND METHODS
STUDY SUBJECTS
Patients were enrolled in Department of Urology (Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India) between January 2007 and June, 2009. Symptomatic men for lower urinary tract infection suspected to have PCa based on serum PSA of > 4 ng/mL and/or abnormal DRE were further subjected to systematic ultrasound-guided needle biopsies. The primary end point was the histological presence of adenocarcinoma of the prostate in the biopsy specimen. Tumour grade was evaluated in PCa samples by the Gleason scoring system [10] . After histological confirmation, 175 cases of adenocarcinoma of prostate were inducted in the study. All the participants in the study were unrelated individuals of similar ethnicity from Lucknow and other adjoining cities of North India. Information on demographic features was obtained through personal interview using a standard clinical proforma.
Age and ethnicity matched healthy individuals ( n = 198) were recruited as controls from men participating in prostate cancer screening programmes of the hospital. None of the controls had a history of cancer and were frequency-matched to cancer cases on age and gender. To test the possibility for population stratification, we used genomic control method as described by Miller et al. [11] .
The total PSA concentrations were determined in PCa, and healthy controls using CanAg EIA kits (Fujirebio Diagnostics Inc., Goteborg, Sweden). Control individuals with PSA concentrations > 4.0 ng/mL and/or abnormal DRE were excluded. The study was conducted with prior informed and written consent and with the approval of the Institute research ethics board.
ASSESSMENT OF CIGARETTE SMOKING/ TOBACCO CHEWING HISTORY
Participants were enquired about their tobacco chewing habits and accordingly grouped into non-tobacco and tobacco chewers. Information collected during the interview included demographic data, smoking history, family history of cancer, and medical history. An individual who had never smoked or had smoked < 20 packs of cigarettes in his lifetime was defined as a never-smoker. An individual who had smoked at least 20 packs of cigarettes in his lifetime was defined as 'ever-smoker' . Ever-smokers included former smokers who had quit smoking for ≥ 1 year before recruitment and current smokers, who were still smoking. Both cases and controls were subjected to similar protocol/questionnaires by the same interviewer. The response rate in both case and controls were < 80%
PATIENTS FOLLOW UP AND STUDY ENDPOINT
Clinical outcomes were obtained for 57 patients who had androgen-deprivation therapy (ADT) with medical or surgical castration. A maximum of 36 months followup was conducted with a mean follow up of 19.3 months. Study endpoint was taken as a patient on ADT progressing to hormone refractory prostate cancer (HRPC), which was defined as the first increase in PSA concentrations in a series from the PSA nadir after starting ADT.
DNA EXTRACTION AND GENOTYPING
Genomic DNA was extracted from peripheral blood mononuclear cells using salting-out method [12] . The CASP-9 − 1263 A > G genotype were determined using a PCRrestriction fragment length polymorphism assay, and the − 293 del/ins genotype was tested using a PCR followed PAGE. The methodology was adopted from Park et al. [8] . CASP8 − 652 6N ins/del polymorphism was genotyped using a modified methodology by Sun et al. [9] . The CASP8 − 652 6N ins/del polymorphism gene locus was amplified using the primers, as stated by Sun et al. [9] , followed by differentiating different genotypes by running on 20% acrylamide gel electrophoresis.
QUALITY CONTROL
To minimize genotyping errors 5% of the samples from patients and controls including samples of each genotype were sequenced to evaluate the quality of genotyping, which showed 99% concordance in re-genotyping results. Genotyping was performed without knowledge of the case or control status by using code numbers.
STATISTICAL ANALYSIS
The sample size was calculated and found to be adequate using QUANTO software, version 1.0 (http://hydra.usc.edu/gxe) for the genetic marker. Sample size achieved 80% of the statistical power. A two-tailed P value of less than 0.05 was considered statistically significant. A χ 2 analysis was used to assess deviation from Hardy-Weinberg equilibrium. Association of CASP9 and CASP8 genotypes with risk of PCa was analysed by binary logistic regression test. Patients and controls were used as dependent variable and genotypes, age, cigarette smoking and tobacco chewing were used as covariates. Risk was expressed as odds ratio (OR) with 95% CI (confidence intervals). Wild type genotype/ allele of CASP8 and CASP9 promoter polymorphisms were taken as reference in risk analysis. The ORs were also adjusted for the confounding factors such as age, cigarette smoking, and tobacco chewing and alcohol consumption by binary logistic regression. Hazard for a patient on ADT advancing to HRPC was calculated for CASP8 and CASP9 variants using Cox regression taking time from ADT to HRPC as time and progression of patient to HRPC was taken as event.
Further Kaplan-Meier analysis was done to calculate the role of CASP polymorphism on time to HRPC. Statistical significance was taken as P < 0.05. All statistical analyses were performed with the SPSS ver. 11.5 (SPSS Inc., Chicago, IL, USA) statistical software package.
Risk estimates were also calculated for a codominant genetic model using the most common homozygous genotype as reference. Tests of linear trend using an ordinal variable for the number of copies of the variant allele (0, 1 or 2) were conducted to assess potential dose-response effects of genetic variants on PCa risk. In addition, cancer being a multifactorial disease, it is unlikely that any single genetic polymorphism would affect the clinical outcome of patients with cancer significantly, thus it is important to take a pathway-based analysis of multiple polymorphic genes. Thus, we also analysed the number of total variant alleles in CASP8 polymorphisms studied. To further explore potential interaction between the CASP8 polymorphism and tobacco smoking, we tested the null hypotheses of multiplicative gene-smoking interaction by evaluating departure from multiplicative interaction model including main-effect variables and their product terms in logistic regression model. Standard adjustments for multiple testing, such as Bonferroni correction, are too conservative as they assume that tests are independent, which is usually not the case when multiple tests are applied on the same data set.
EVALUATION OF CODING SINGLE NUCLEOTIDE POLYMORPHISMS
The Polymorphism Phenotyping algorithm (PolyPhen) (http://www.bork.embl.de/ PolyPhen/) was chosen for functional impact prediction of CASP8 polymorphism. PolyPhen is a computational tool for identification of potentially functional nonsynonymous SNPs. Predictions are based on a combination of phylogenetic, structural and sequence annotation information characterizing a substitution and its position in the protein.
RESULTS
DEMOGRAPHICAL AND CLINICAL DETAILS
No statistically significant differences were found between PCa cases and controls in terms of mean age distribution, suggesting that the frequency matching was adequate ( Table 1 ). The genomic control method ruled out the possibility of population stratification in our study. There was no significant difference in frequency between cigarette smokers and non-smokers, or tobacco chewers and non-chewers both in cases and controls. The clinical details suggested higher number of patients had aggressive disease (Gleason grade > 7 = 41%). About 48.8% of patients showed evidence of bone metastasis after bone scan. All cancer patients were incident cases and none of the controls had family history of cancer.
GENOTYPE AND ALLELIC FREQUENCY DISTRIBUTION BETWEEN CONTROLS AND CASES AND RISK ASSOCIATED WITH PCa
The genotype distributions of CASP9 − 1263 and CASP8 − 652 polymorphisms among the controls were in Hardy-Weinberg equilibrium but CASP9 − 293 del/ins polymorphism was not. Therefore, we have not considered any result associated with CASP9 − 293 del/ins polymorphism. Genotype frequency distribution demonstrated association of CASP9 − 1263 polymorphism with PCa ( χ 2 P = 0.003). The unconditional logistic regression model (adjusted with age of diagnosis, cigarette smoking or tobacco chewing habits) showed the AG genotype to be associated with decreased susceptibility to PCa (OR 0.47, 95% CI 0.29-0.78, P = 0.003). However, the GG genotype did not show any significant association. When both the genotypes were combined (AG + GG) then they demonstrated decreased risk for PCa susceptibility (OR 0.6, 95% CI-0.39-0.92, P = 0.02). None of the other variants illustrated any association with PCa risk. The distributions of the CASP9 − 1263 A > G, − 293 del/ins and CASP8 − 652 del/ins genotypes among cases and controls are shown in Table 2 .
CASP GENOTYPES AND RISK ASSOCIATED WITH GLEASON GRADE
CASP9 and CASP8 variants were further analysed for risk associated with less aggressive or highly aggressive disease based on Gleason grade. The histological grades from a patient are assigned a value ranging from 1 to 5 based on two most common patterns of growth (well differentiated and poorly differentiated). These two values were added to a combined score. Patients were then categorized into three groups based on this combined score (Gleason score < 7, low grade; Gleason score = 7, less aggressive (Fig. 1 ). Log rank P value was, however, not significant (log rank P = 0.081).
DISCUSSION
Genes encoding caspase, the executioner of apoptosis have been detected in human cancers.
This study investigated the potential association between CASP9 (−1263 A > G, −293del/ins) and CASP8 (−652) polymorphisms and the risk of prostate cancer. Our results provided evidence that susceptibility and progression of prostate cancer is influenced by genetic polymorphism of the CASP9 gene. Moreover, our results 
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suggest involvement of CASP8 gene variant in risk associated with progression of PCa to hormone refractory state.
Caspase 9 is an important caspase of intrinsic pathway. It is initiated by release of cytochrome c from mitochondria in response to various cytotoxic signals such as DNA damage. Cytochrome c interaction with Apaf-1, proCASP-9 and dATP results in formation of multiprotein complex apoptozome. Once a bond to apoptozome is formed, caspase-9 is activated, which triggers other effectors such as caspases 3 and 7 [11] . We identified that presence of the G variant of the CASP9 −1263 polymorphism is associated with decreased susceptibility to PCa. Earlier studies have demonstrated that G allele of CASP9 −1263 is associated with increased expression [3] .
Several studies have demonstrated that CASP9 gene variants are associated with influencing susceptibility to various cancers. CASP9 −1263 G variant has also been associated with a decreased risk for lung cancer [3] . An analysis of the potential transcription factor-binding sites using the ALIBABA2 program [12] showed that the −1263 A to G change leads to the creation of an additional simian virus-40 protein 1-binding site. Therefore, it is possible that the predicted change in the putative transcription factor binding site resulting from the −1263 A > G polymorphism might lead to enhanced promoter activity. This suggests that the 'higher production' for CASP9 may offer protection against the development of prostate cancer. This is biologically plausible because CASP9, as an initiator caspase, plays an important role in the apoptosome-driven apoptosis pathway, which is essential for eliminating mutated or transformed cells from the body [13, 14] . Another interesting finding of this study was that higher production of CASP9 −1263 A>G polymorphism was associated with an increased risk for progressive disease. This may be demonstrated by the fact that the variant may also be present in the malignant cells themselves, and therefore may be associated with increased risk for progression.
Regulation of the apoptotic process in prostate cancer cells is essential and is maintained by androgen withdrawal therapy. However, patients have relapse to an androgen-insensitive state in which the outcome is uniformly fatal. Failure of these cells to die at androgen withdrawal is believed to be partly caused by a defect in the initiation step of the apoptotic process as well as the acquisition of genetic mutations favouring survival in the absence of androgen [15, 16] . The CASP8 −652 6N del variant has been shown to decrease expression of CASP8 by destroying a binding site for transcription activator Sp1. Therefore, it may also be responsible for decreased apoptosis in androgen-insensitive cells. The CASP8 −652 6N del variant has been deemed to confer protection against developing lung as well as oesophageal, stomach, colorectal, breast and cervix cancer [8] . However, our results demonstrate its role in conferring risk for early advancement of PCa to the androgeninsensitive state. These results clearly reveal that the CASP8 -652 gene may be responsible for low apoptosis and, therefore, lead to early development of the androgen-independent state in PCa patients on androgen withdrawal therapy. However, our results were not statistically significant, and this observation again could be related to low number of androgen therapy cases (n = 57). This seems to be a limitation of our study.
This is the first study that associates CASP9 and CASP8 gene polymorphisms with risk of PCa. However, this is a pilot study and further studies in large cohort with various ethnicity would be beneficial to confirm our results.
In conclusion, promoter polymorphisms of CASP9 (−1263 A > G) may have influence on the CASP9 promoter activity and are therefore significantly associated with reduced risk of PCa, indicating that this variant allele may confer protection against PCa. However, this promoter polymorphism may increase risk for progression of PCa. Moreover, CASP8 (−652) may be responsible for decreased apoptosis in patients on androgen withdrawal therapy, thereby leading to early advancement to androgen-insensitive state.
Introduction
Prostate cancer (CaP) is the most common non-skin cancer among men, and its incidence is rising rapidly in most countries [1] . The incidence rate of CaP in India is low compared with Western countries, and CaP is the sixth most commonly diagnosed cancer among men [2] . Despite its high morbidity, the etiology of CaP remains largely unknown. It is well established that genetic factors also play an important role in pathogenesis of CaP [3] . Therefore there is increasing interest in the role that genetic variants, such as single nucleotide polymorphic (SNPs) variants, play in CaP risk.
DNA initiates a series of signals that call upon an arrest of cell cycle for the completion of repair activities or activate the apoptotic pathway if the damage to DNA is unrepairable. Cell cycle regulation and apoptosis are essential defenses against cancer [4, 5] . Functional relevance of some variants in cell cycle and apoptosis genes has been evaluated and inconsistent results have been reported on the associations between these variants and a number of cancer sites. Thus, it is plausible that genetic variation in critical pathways of DNA repair, cell-cycle control, or apoptosis may contribute to inter-individual variation in susceptibility to CaP.
The human mouse double-minute 2 protein (MDM2) located on chromosome 12q14.3-q15 is a cellular E3 ligase able to ubiquinate and degrade p53 [6] . As a key negative regulator of p53, overexpression of Mdm2 is associated with accelerated tumor progression and lack of response to therapy in various human malignancies. Although MDM2 is rarely mutated, it is highly polymorphic. A single-nucleotide polymorphism (SNP) in the promoter of the MDM2 gene (SNP309, T Ͼ G) (rs2279744) was found that increases mRNA and protein levels [7] . Several studies have analyzed the impact of the MDM2 SNP309 on cancer risk. Alterations in the p53 pathway are already described in CaP including MDM2 protein overexpression in about 30%-45% of the analyzed tumors [8] . SNP309 was thus postulated as a potential modulator of cancer susceptibility. It has been suggested that the single nucleotide polymorphism 309 (SNP309, T Ͼ G) in the promoter region of the MDM2 gene is important for tumor development; however, with regards to CaP, inconsistent associations have been reported worldwide. It is speculated that these conflicting results may have arisen due to different patient subgroups and ethnicities studied. For the first time, this study explores the effect of the MDM2 SNP309 genotype on North Indian cohort of CaP patients.
Cyclin D1 (CCND1) is a key protein in the regulation of the cell cycle at the G1 to S phase transition, and is essential for regulation of proliferation, differentiation, and transcriptional control [9] . Cell cycle dysregulation plays a central role in a variety of malignancies including CaP [10] . Many association studies have focused their attention to the functionally significant 870 G Ͼ A (rs134556, Pro242Pro) polymorphism in CCND1, which creates 2 different splice variant transcripts. The normal transcript encodes exon 5, which is essential for ubiquitin-mediated proteolysis, whereas the other transcript lacks the destruction box in exon 5 and increases the half life of CCND1 [11] . Many studies have shown that variation in cell cycle genes may be associated with risk of breast cancer [12] , CaP [13] , but not in colorectal cancer [14] .
Fas (also known as TNFRSF6/CD95/APO-1), being expressed on the surface of cells, encoding a member of the tumor necrosis factor super family, interact to initiate the death signal cascade, which results in apoptotic cell death. The Fas gene located at chromosome 10q24.1 consists of nine exons and eight introns. Two single-nucleotide polymorphisms have been widely reported in the promoter region. A G-to-A transition at position Ϫ1377 (Fas Ϫ1377 G Ͼ A, rs2234767) is located within the consensus sequences of the stimulatory protein 1 (SP-1), and an A-to-G at position Ϫ670 (Fas Ϫ670 A Ͼ G, rs1800682) is in the signal transducers and activators of the transcription 1 (STAT1) transcription factor binding site. These 2 polymorphisms may deregulate promoter activity and affect Fas gene expression [15] [16] [17] .
In view of the crucial role that MDM2, CCND1, and Fas interaction plays in the cell cycle checkpoint, DNA repair, apoptotic cell death, and the reported functional significance of their variants, we hypothesized that genetic variations in these genes might trigger genotypic variation in susceptibility to CaP. To the best of our knowledge, no study has been reported from India on the association of these polymorphisms with the risk of CaP.
Materials and methods
Study subjects
Patients were enrolled in Department of Urology (Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow) between January 2007 and June, 2009. Symptomatic men for lower urinary tract infection (LUTS) suspected to have CaP based on serum PSA Ͼ4 ng/ml and/or abnormal digital rectal examination (DRE) were further subjected to systematic ultrasound-guided needle biopsies. The primary end point was the histologic presence of adenocarcinoma of the prostate in the biopsy specimen. Tumor grade was evaluated in CaP samples by the Gleason scoring system [18] . After histologic conformation, 192 cases of adenocarcinoma of prostate were inducted in the study. All the participants in the study were unrelated individuals of similar ethnicity from Lucknow and other adjoining cities of North India. Information on demographic features was obtained through personal interview using a standard clinical proforma.
Age-and ethnicity-matched healthy individuals (n ϭ 224) were recruited as controls from men participating in CaP screening programs of the hospital. None of the controls had history for cancer and were frequency-matched to cancer cases on age and gender.
The total prostate specific antigen (PSA) levels were determined in CaP and healthy controls using CanAg EIA kits (Gothenburg, Sweden). Control individuals with PSA Ͼ4.0 ng/ml and/or abnormal DRE were excluded. The study was conducted with prior informed written consent and with the approval of the Institute research ethics board.
Genotyping
DNA was extracted from peripheral blood lymphocytes by salting out method [19] . Polymorphisms in MDM2 T309G (rs2279744), CCND1 G870A (rs134556), Fas G670A (rs1800682), and Fas G1377A (rs2234767) were analyzed by PCR restriction fragment length polymorphism (RFLP). Details of primers and cycle conditions were referred as described earlier [20 -22] . Positive and negative controls were used in each genotyping assay, and 5% of randomly selected samples were re-genotyped by other lab personal with 100% concordance.
Statistical analysis
The sample size was calculated and was found to be adequate using QUANTO software, ver. 1.0 (http:ϭ hydra.usc.eduϭgxe) for the genetic marker. Sample size achieved 80% of the statistical power. A 2-tailed P value Ͻ0.05 was considered statistically significant. Chi-square ( 2 ) analysis was used to assess deviation from HWE and to compare the genotypeϭalleleϭhaplotype frequency between patients and controls. Odds ratios (ORs) were obtained by unconditional logistic regression analysis and adjusted for age and smoking as a continuous variable. CaP patients with different Gleason gradesϭbone metastasis were identified using the same statistics as mentioned. All the statistical analyses were conducted using the SPSS software, ver. 11.5 (SPSS, Chicago, IL). A P value Ͻ0.05 was regarded statistically significant.
Diplotype analysis
Diplotype were constructed and their frequencies assessed using the maximum-likelihood method, using an expectationmaximization algorithm by performing 100,000 permutations through software Arlequin (ver. 2.0). OR was calculated using unconditional logistic regression for risk diplotype taking the wild-type diplotype as reference.
Results
Demographical and clinical details of study subjects
A total of 416 individuals (192 CaP and 224 controls) were analyzed in the study. There was no statistical difference between age of the CaP patients (62.6 Ϯ 8.9 years) and healthy controls (59.1 Ϯ 10.4 years) and smoking habits (P ϭ 0.327). As expected, there was a high degree of statistical difference between serum PSA of CaP patients (221 Ϯ 57.4 ng/ml) and controls (2.3 Ϯ 0.8 ng/ml). Majority of the patients had high Gleason grade at the time of diagnosis (Gleason score 7 in 29.7% and Gleason score Ͼ7 in 44.8%), and 41.8% of patients were diagnosed to have bone metastasis (Table 1) .
Association of MDM2, CCND1, and Fas genotype variants with CaP risk
The observed genotype frequencies of all the polymorphisms were in agreement with Hardy-Weinberg equilibrium (HWE) in the controls except Fas-1377 (G Ͼ A) gene polymorphism (P ϭ 0.035). To evaluate the association between genetic variant with risk of CaP, we compared MDM2, CCND1, and Fas genotype frequency distribution in the CaP and control group shown in Table 2 . MDM2 homozygous variant GG genotype demonstrated statistically significant reduced risk of developing CaP (Pϭ 0.041; OR, 0.59). The G allele carrier (GT ϩ GG) also showed a reduced risk with significant p value (P ϭ 0.009; OR, 0.56). This effect was also observed in case of alleles (Pϭ 0.024; OR, 0.73). The G allele frequency was higher in controls (54.5%) compared with cases (46.6%). Variant genotype AA of CCND1 demonstrated 1.8-fold significant risk associated with CaP (Pϭ 0.018; OR, 1.86). The variant allele frequency was higher in cases (63.3) than in controls (53.3%), the results showed statistically significant risk with CaP (Pϭ 0.04; OR, 1.50). Our results further showed that Fas gene does not influence susceptibility to CaP.
Further, to elucidate the combined influence of these polymorphisms, we constructed Fas-670 and Ϫ1377 diplotype (Table 3) . Interestingly diplotype results confer that G of Fas-670 and A of-1377 diplotype (GA) to be associated with 1.63 folds (P ϭ 0.024; OR, 1.63) increased risk with CaP.
Association of MDM2, CCND1, and Fas gene polymorphism with tumor stage/grade
For genotypic comparison the patients with different Gleason grades were subcategorized into 3 group (low grade Ͻ7, intermediate grade 7, high grade Ͼ7) based on degree of differentiation of cells (Table 4) . When the genotype frequencies of MDM2, CCND1, and Fas variants were compared with these 3 Gleason groups, we did not find any significant risk associated with the grades of disease (Table  4) . However, we observed a reduced risk for the individuals with the GA genotype of Fas-1377 (G Ͼ A), due to less incidence of intermediate tumor grade of CaP in the specific genotype (P ϭ 0.042; OR, 0.36). CaP ϭ prostate cancer; PSA ϭ prostate-specific antigen. * Numbers may not add to the total because of some missing data.
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Analysis of MDM2, CCND1, and Fas gene polymorphism with risk for bone metastasis
We also studied MDM2, CCND1, and Fas gene variants and their risk associated with bone metastasis. The CaP patients were stratified into 2 groups, 1 with positive and the other with negative bone metastasis. When these 2 groups were analyzed for risk of susceptibility for bone metastasis with these 4 gene polymorphism, we did not find any significant risk (Table 5 ). However, A allele carrier (GA ϩ AA) of Fas 670 showed a reduced risk (P ϭ 0.037; OR, 0.42).
Interaction of MDM2, CCND1, and Fas gene polymorphism with smoking habit in CaP
We evaluated the gene-smoking interaction to study the modulation of CaP risk with respect to MDM2, CCND1, and Fas gene polymorphisms. We grouped the CaP patients into 2 groups, one nonsmoker (never smoked) and the other as smokers (smoking more than 5 years). On analyzing the genotype frequency between these 2 groups for susceptibility to CaP, none of these polyCaP morphisms demonstrated association (data not shown).
Discussion
In the present study, we explored the association of MDM2, CCND1, and Fas gene polymorphisms with risk of CaP in a North Indian population. The MDM2 SNP309 may be a plausible cancer predisposing allele due to the crucial role of MDM2 in the cellular p53 pathway. The T to G variant was shown to result in increased MDM2 synthesis and was found to be correlated with the risk of cancer at an early onset of tumor formation at various organ sites [23] . OR ϭ odds ratio; CI ϭ confidence interval. Mandal, R.D. Mittal / Urologic Oncology: Seminars and Original Investigations xx (2010) xxx Overexpression of MDM2 and its clinical consequences have been reported in CaP [24] . In our cohort, MDM2 309GG allele demonstrated reduced genetic susceptibility to CaP. These results were consistent with the findings of Stoehr et al. 2008 in CaP [25] . In another study from India, decreased associations of MDM2 SNP309G along with p53 Arg72Pro heterozygous variant with premenopausal breast cancer risk was also reported [26] . Recently, 309G allele has been reported to be associated with reduced risk in epithelial ovarian cancer [27] . Few studies with conflicting observations have also been reported, as Hong et al., 2005 , observed the MDM2 GG genotype to be associated with risk of ESCC compared with the GT or TT genotype [28] . It is speculated that these conflicting results may have arisen due to different patient subgroups and/or ethnic groups studied. The second association of interest was with CCND1 G870A SNP. We found significant association between the CCND1 gene polymorphism and susceptibility to CaP, and AA genotype contributed to a 1.8-fold increased risk of CaP. The CCND1 A allele showed significantly increased risk of CaP. Similar result were reported by , where AA genotype showed significant association with CaP in Japanese men [29] . The mechanism by which the CCND1 A allele enhances carcinogenesis in the CaP cell pathway remains unknown. CCND1 mRNA is alternately spliced to produce transcripts a and b, which occur simultaneously in a variety of tissues The main difference in the cyclin D1 proteins encoded by the 2 transcripts is in the C-terminal PEST-rich region (destruction box) encoded by exon 5, which could be responsible for rapid intracellular degradation [30] . The AA genotype increases the products of transcript b in tumor tissue cells, resulting in an increase of an altered protein that lacks the PEST-rich region and an increase in the half-life of the protein [31] .
The Fas-670 G Ͼ A and Ϫ1377 G Ͼ A polymorphisms destroy stimulatory protein 1 (Sp1, an important transcriptional activator) and signal transducer and activator of transcription 1 (STAT1) protein binding element, respectively, diminishing the promoter activity and decreasing Fas expression [17] . In this case-control study, no evidence for an association between the Fas polymorphisms and CaP was observed. Similar results were observed in another study from China by Wang et al., 2009 in gastric cancer [32] . The diplotype analysis of Fas-670 G Ͼ A and Ϫ1377 G Ͼ A, one of the diplotype (G-A) demonstrated higher risk with CaP, but no altered risk was associated with other diplotype. The combined genotype, however, was associated with CaP risk.
On analyzing these 4 gene polymorphism with Gleason grade and bone metastasis, heterozygous GA genotype of Fas-1377 (G Ͼ A) was associated with reduced risk with intermediate Gleason grade. The A allele carrier (GA ϩ Mandal, R.D. Mittal / Urologic Oncology: Seminars and Original Investigations xx (2010) xxx AA) of Fas G670A also showed reduced risk of bone metastasis with CaP.
In conclusion, MDM2 GG genotype had an overall reduced risk. CCND1 variant genotype was associated with increased risk of CaP. The combined genotype of Fas was found to be associated with CaP risk. Additional studies of functional DNA repair gene polymorphisms in a large cohort of different ethnicities are required to augment the etiology in the pathogenesis of CaP. Mandal, R.D. Mittal / Urologic Oncology: Seminars and Original Investigations xx (2010) xxx
Introduction
Prostate cancer (PCa) is the most common male malignancy in the Western world, though its incidence varies widely according to race. In the Western world, it is a second leading cause of cancer death in males (Jemal et al., 2008) . Literature review discloses Asians with the lowest incidence, and in India it is ranked as the sixth most commonly diagnosed cancer in men . In spite of these dismal statistics, the etiology of PCa remains largely unknown. Variation in incidence and mortality rate from PCa around the world suggests that it is multifactorial and polygenic in origin. Polymorphic variations in humans may be responsible for interindividual differences in susceptibility to multifactorial diseases. It is well established that genetic factors also play an important role in pathogenesis of PCa . Several risk factors have been identified, the main factors being age (Sakr et al., 1996) , family history (Bratt, 2002) and ethnic origin (Ben-Shlomo et al., 2008) . PCa is uncommon in men younger than 50 years, but 80% of men older than 80 years were found to have cancerous cells in their prostate at the time of death (Sakr et al., 1996) . Estimates suggest that between 30 and 40% of all early onset cases of PCa (<55 years) are caused by inherited factors (Bratt, 2002) .
DNA repair is an important mechanism for maintaining the integrity of DNA. Single nucleotide polymorphisms (SNPs) located in DNA repair genes could be responsible for substantial alterations in DNA repair capacity (DRC). Several studies have demonstrated that polymorphisms in DNA repair genes that are responsible for maintaining genomic integrity are modifiers of tumorigenesis risk Vodicka et al., 2004) . Eukaryotic cells have developed two pathways to repair DNA double-strand breaks (DSBs): the homologous recombination and the nonhomologous end-joining (NHEJ) pathways. NHEJ plays a predominant role under most conditions in mammalian cells (West, 2003) .
ReseaRch aRtIcle
Do polymorphisms in XRCC4 influence prostate cancer susceptibility in North Indian population?
The DNA repair pathway is essential for maintaining genomic stability of mammalian cells. Deficiencies in the DNA repair system are likely to cause chromosomal aberrations, which in turn lead to cell malfunctioning, cell death and tumorigenesis (van Gent et al., 2001 ). Many genes play important roles in the repair pathway, for example, the X-ray cross-complementing group 4 (XRCC4; located in the 5q13-q14 region) gene, a key component of NHEJ repair pathway, is found to restore DNA DSB repair and has the ability to support V(D)J recombination (Li et al., 1995) . The XRCC4 gene product interacts directly with Ku70/Ku80 (Mari et al., 2006) and it is hypothesized that XRCC4 serves as a flexible join between Ku70/Ku80 and its associated protein Ligase4. A number of recognized SNPs of the XRCC4 gene have been reported to be associated with various cancers, indicating that they might play common and central roles in various cancers. Other studies have shown that XRCC4 is required for precise end-joining of blunt DNA DSBs in mammalian fibroblasts (van Heemst et al., 2004) . The gene targeted mutation studies demonstrate that differentiating lymphocytes and neurons strictly requires the XRCC4 end-joining proteins. The targeted inactivation of XRCC4 gene leads to late embryonic lethality accompanied by defective lymphogenesis and neurogenesis manifested by extensive apoptotic death of newly generated cells (Gao et al., 1998) . Thus, it is reasonable that polymorphisms of XRCC4 gene can be sustained in the genome during long-term process of carcinogenesis. These findings suggest that mutations of the XRCC4 gene induce serious syndromes from a very early age. As PCa most commonly affects elderly men, these mutations are maybe suitable targets for PCa biomarkers. We therefore focused our study on the SNPs of XRCC4, hypothesizing that, though variant genotypes of SNPs may not cause lethal injuries in younger males, they might slightly increase the possibility of genomic instability and lead to PCa carcinogenesis with increasing age.
Since DNA repair gene alterations have been reported to cause a reduction in DRC, we hypothesized that DNA repair gene polymorphisms may be risk factors for PCa. To ensure this proposition, we determined the genotypic frequency for polymorphisms of the XRCC4 gene at G-1394T (rs6869366), intron 3 (rs28360071), intron 7 (rs28360317) and intron 7 (rs1805377) (Figure 1 ), using a polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) method. To the best of our knowledge, data in PCa is sparse and only one study has been reported from Taiwanese, this is the first study carried out to evaluate the contribution of XRCC4 polymorphisms in PCa in India.
Material and methods
Study subjects
Patients were enrolled in Department of Urology (Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh) between January 2007 and June 2009. Symptomatic men for lower urinary tract infection suspected to have PCa based on serum prostate-specific antigen (PSA) of >4 ng/ml and/or abnormal digital rectal examination (DRE) were further subjected to systematic ultrasound-guided needle biopsies. The primary end point was the histologic presence of adenocarcinoma of the prostate in the biopsy specimen. Tumor grade was evaluated in PCa samples by the Gleason scoring system . After histological conformation, 192 cases of adenocarcinoma of prostate were inducted in the study. All the participants in the study were unrelated individuals of similar ethnicity from Lucknow and other adjoining cities of North India. Information on demographic features was obtained through personal interview using a standard clinical proforma.
Age-and ethnicity-matched healthy individuals (n = 224) were recruited as controls from men participating in PCa screening programs of the hospital. None of the controls had history for cancer and were frequency matched to cases on age.
The total PSA levels were determined in PCa, and healthy controls using CanAg EIA kits, Goteborg (Sweden). Control individuals with PSA >4.0 ng/ml and/ or abnormal DRE were excluded. The study was conducted with prior informed and written consent and with the approval of the Institute research ethics board.
Genotyping
DNA was extracted from peripheral blood lymphocytes by salting out method . Individual SNP found on XRCC4 were analyzed by PCR-RFLP. Details of primers and cycle conditions were referred as described earlier . The PCR products of XRCC4 intron 3 (rs28360071) polymorphism were 109 bp for the Del allele type and 139 bp for the Ins allele type, respectively. The PCR products of XRCC4 intron 7 (28360317) polymorphism were 239 bp for CCT-positive form and no product for CCT-negative form. The PCR products were studied after digestion with HincII and TasI restriction enzymes for XRCC4-1394 G > T (rs6869366) (cut from 300 bp T type into 200 + 100 bp G type) and XRCC4 intron 7 (rs1805377) (cut from 237 bp G type into 79 + 158 bp A type), respectively. Positive and negative controls were used in each genotyping assay and 5% of randomly selected samples were regenotyped by other lab personal with 100% concordance.
Statistical analysis
Power of the study was calculated using Quanto software version 1.0 (http://hydra.usc.edu/gxe) with input of the following variables: case-control study design, significance level (α) <0.05 (2 sided), model of inheritance = log additive, allele freq, genetic effect for odds ratio (OR) (≥1.6 or ≤0.6). The present study achieved 80% of the statistical power. χ 2 Analysis was used to assess deviation from Hardy-Weinberg equilibrium (HWE) and to compare the genotype = allele = haplotype frequency between patients and controls. ORs were obtained by unconditional logistic regression analysis and adjusted for age and smoking as a continuous variable. PCa patients with different Gleason grades, bone metastasis were identified using the same statistics as mentioned. Bonferroni's correction was applied in case of multiple comparisons using the formula Pc = p × n (Pc represents corrected value where n is the number of comparisons performed). All the statistical analyses were conducted using the SPSS software, version 11.5 (SPSS, Chicago, IL) . A p value <0.05 was regarded statistically significant.
Haplotype analysis
Haplotypes were constructed and their frequencies assessed using the maximum-likelihood method, using an expectation-maximization algorithm by performing 100,000 permutations through software Arlequin (version 2.0). OR was calculated using unconditional logistic regression for risk haplotypes taking the wild-type haplotype as reference.
Results
Demographical and clinical details of study subjects
A total of 416 individuals (192 PCa and 224 controls) were analyzed in the study. There was no statistical difference between age of the PCa patients (62.6 ± 8.9 years) and healthy controls (59.1 ± 10.4 years) and smoking habits (p = 0.327). As expected, there was high degree of statistical difference between serum PSA of PCa patients (221 ± 57.4 ng/ml) and controls (2.3 ± 0.8 ng/ml). Majority of the patients had high Gleason grade at the time of diagnosis (Gleason score 7 in 29.7% and Gleason score >7 in 44.8%) and 41.8% of patients were diagnosed to have bone metastasis (Table 1) .
Association of XRCC4 genotype variants with PCa risk
The observed genotype frequencies of all the polymorphisms were in agreement with HWE in the controls. To evaluate the association between genetic variant with risk of PCa, we compared XRCC4 genotype frequency distribution in the PCa and control group shown in Table 2 . Carriers of the GG genotype of XRCC4-1397 (rs6869366) were at reduced risk (p = 0.048; OR = 0.34). In contrast, XRCC4 intron 3 (rs28360071) variant genotype (Del/ Del) demonstrated increased risk with PCa (p = 0.013; OR = 2.99). After combining the heterozygous and homozygous (Ins/Del + Del/Del) in both groups there was still an evident increase risk of 1.5-fold (p = 0.042; OR = 1.56). This effect was also observed in case of alleles (p = 0.002; OR = 1.75). Variant genotype (Del/Del) of XRCC4 Intron 7 (rs28360317) demonstrated twofold significant risk associated with PCa (p = 0.007; OR = 2.05). Variant allele (Del) also showed marginal significant risk (p = 0.010; OR = 1.49). Our results further showed that XRCC4 Intron 7 (rs1805377) gene does not influence susceptibility to PCa.
Association with haplotypes
Further, to elucidate the combined influence of these polymorphisms, we constructed XRCC4 haplotypes of the four polymorphisms examined (rs6869366, rs28360071, rs28360317, rs1805377; Table 3 ). For statistical advantage, 11 of the haplotypes with a frequency of <5% were excluded from further analysis. The remaining three haplotypes were subjected for further statistical analysis. Interestingly, haplotypes T/ Ins/Del/A (p < 0.001; OR = 3.73) showed increased risk for PCa.
Association of XRCC4 gene polymorphism with tumor stage/grade
For genotypic comparison the patients with different Gleason grades were subcategorized into three groups (low grade <7, intermediate grade 7, high grade >7) based on degree of differentiation of cells (Table 4) . When the genotype frequencies of XRCC4 variants were compared with these three Gleason groups, a significant association was observed for the variant allele carrier (TG + GG) of XRCC4 (rs6869366) (Pc = 0.016; OR = 2.91) with high Gleason grade. Combination of heterozygous and homozygous (Ins/Del + Del/Del) of XRCC4 intron 3 (rs28360071) showed significant association but when Bonferroni correction was applied the significance has been lost (Pc, 0.076). Variant allele carrier (AG + GG) of intron 7 (rs1805377) also exhibited significant risk (Pc, 0.028; OR, 2.87) with high Gleason grade. We did not find any significant risk associated with XRCC4 Intron 7 (rs28360317).
Analysis of XRCC4 gene polymorphism with risk for bone metastasis
We also studied XRCC4 gene variants and their risk associated with bone metastasis. The PCa patients were stratified into two groups, one with positive and the other with negative bone metastasis. When these two groups were analyzed for risk of susceptibility for bone metastasis For personal use only. with these four polymorphisms, we did not find any significant risk (Table 5) .
Interaction of XRCC4 gene polymorphism with smoking habit in PCa
We evaluated the gene-smoking interaction to study the modulation of PCa risk with respect to XRCC4 gene polymorphisms. We grouped the PCa patients into two groups, one nonsmoker (never smoked) and the other as smokers (smoking more than 5 years). On analyzing the genotype frequency between these two groups for susceptibility to PCa, none of these polymorphisms demonstrated association (data not shown).
Discussion
Disruption of genomic integrity contributes to malignant transformation and subsequent cancer development. The repair of DNA damage plays a key role in maintaining genomic integrity. Because DNA repair enzymes are correctives for DNA damage induced by carcinogens and environmental factors, it is very likely that SNPs in DNA repair genes may play an important part in both cancer susceptibility and anticancer treatment response. The present study has investigated the role of XRCC4 gene polymorphisms in PCa susceptibility. The XRCC4 gene is necessary for DNA ligation in NHEJ pathway, which is responsible for repairing most DSBs (Riha et al., 2006; Yurchenko et al., 2006) . SNP G > T (rs6869366) found in promoter region of XRCC4 may have functional regulatory significance and showed an association with reduced PCa risk. Our result is discordant with previous report, suggesting heterozygous genotype GT to be associated with PCa and lung cancer in Taiwan (Chang et al., 2008; Hsu et al., 2009 ). However, findings need to be replicated in additional study populations, particularly since homozygote variants were low in our control populations (6.3%), whereas Chang et al. (2008) and Hsu et al. (2009) reported Zero in Taiwan population. Interestingly, we found that the variant genotype Del/Del of XRCC4 (rs28360071) had a strong significant association with PCa risk. Del allele carrier also showed increased risk of PCa. This is in accordance with a recent study by that reported significant risk with oral cancer. Conversely, Chang et al. (2008) did not observe altered risk with PCa.
The second association of interest was with (rs28360317) SNP. We found significant association between the XRCC4 gene polymorphism and susceptibility to PCa, and Del/Del genotype contributed to a twofold increased risk of PCa. The possible mechanism is that people with the risky genotypes, such as variant, may have lower capacity in their NHEJ for the repair of DNA damage caused by carcinogens. This perhaps suggested the contribution of this polymorphism in the etiology of PCa. On the other hand, did not show association with oral cancer and gastric cancer in Taiwan population. It is speculated that these conflicting results may have arisen due to different patient subgroups and/or ethnic groups studied. The XRCC4 (rs1805377) A > G polymorphism involves a substitution of G > A in the intron 7/exon 8 junction region of XRCC4. This SNP potentially abolishes an acceptor splice site at exon 8. Although little is known regarding this SNP in terms of the potential impact on repair capacity of XRCC4 and the consequent risk of carcinogenesis, significant association was not revealed in our study, which was compatible to the observations reported by Wu et al. (2006) and in bladder and oral cancer. The distribution of haplotype was significantly different between the cases and controls, showing increased risk of PCa. This finding demonstrated that combined genotype was associated with PCa.
Moreover, we also analyzed the association of these polymorphisms with clinical characteristics such as tumor grade and bone metastasis. A significant increased risk was observed for variant allele carrier of rs28360071, rs28360317, rs1805377 with high Gleason grade. These findings suggest that these SNPs are involved in progression of PCa. Therefore, our findings might throw some light on understanding the development of the PCa. However none of the polymorphisms were associated with bone metastasis.
The precise mechanism of cancer susceptibility in the elderly is not well understood, but immune function and DNA repair efficiency have been shown to decrease with age, which reduces protection against environmental carcinogens . Thus, there is emerging belief that the intrinsic fidelity of DNA repair mechanisms, such as DSB, may influence ageassociated cancer. Our study has both strengths as well as limitations. High participation rate of eligible cases (98%) and a sample from a homogeneous ethnic background (100% of study participants were from North India only) which reduces the bias due to population stratification. In addition, our study population (both cases and controls) were from all over the state of North India minimizing potential selection bias. Limitations of this study are the small numbers of patients used due to low incident rate of PCa in our country. We also did not consider the analysis of gene-gene interactions. It is possible that the risks observed are the result of interactions but we have not attempted to assess such effects since the estimate of an interaction effect will be unreliable because of small numbers. For this type of analysis, a very large sample size is essential. We also did not adjust for possible differences in lifestyle factors nor account for multiple testing risk due to small number of patients.
In conclusion, these findings suggest that XRCC4 gene could serve as a biomarker of PCa screening and should be a target of cancer prevention. Though our study achieved sufficient (>80%) power due to low incidence rate of PCa in India, nevertheless, a higher number of sample size can warrant more modest results. Additional studies of functional DNA repair gene polymorphisms in a large cohort of different ethnicities are required to augment the etiology in the pathogenesis of PCa.
acknowledgements
We also thankful to Dr. Anil Mandhani and the senior residents for recruitment of patients and organizing health check-up camps from time to time, which was helpful in collecting healthy control blood samples.
